<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04644055</url>
  </required_header>
  <id_info>
    <org_study_id>IECED-110520</org_study_id>
    <nct_id>NCT04644055</nct_id>
  </id_info>
  <brief_title>EUS Share-wave in Patients With Liver Cirrhosis</brief_title>
  <official_title>Endoscopic Ultrasound Share-wave for the Evaluation of Patients With Chronic Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Ecuatoriano de Enfermedades Digestivas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Ecuatoriano de Enfermedades Digestivas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with chronic liver disease may develop progressive hepatic fibrosis. Liver cirrhosis&#xD;
      should be detected at the early stages in order to avoid the complications related to these&#xD;
      two conditions.&#xD;
&#xD;
      The diagnostic work-up of patients with chronic liver disease includes less-invasive&#xD;
      diagnostic methods such as abdominal ultrasonography, transient elastography, upper&#xD;
      endoscopy; and more invasive procedures, mainly liver biopsy and portal pressure gradient&#xD;
      measurement, both with associated risks.&#xD;
&#xD;
      Endoscopic ultrasound offers a benefit of including all diagnostic work-up in a single&#xD;
      procedure. The investigators previously demonstrated that EUS-elastography of the liver and&#xD;
      spleen is reliable marker for predicting liver cirrhosis.&#xD;
&#xD;
      Recently, a quantitative evaluation of fibrosis using share wave elastography was introduced,&#xD;
      mainly for the pancreatic tumor fibrosis measurement (2). Elastography measures the&#xD;
      elasticity of tissues (hardness); whereas share wave measures the tissue elasticity as the&#xD;
      elastic modulus by measuring the share wave velocity. Share wave measurement will be&#xD;
      performed with the Arietta 850 Endoscopic ultrasound console using a linear ultrasound video&#xD;
      gastroscope EUS-J10 (Pentax Medical, Hoya Corp, Japan). The investigators proposed the&#xD;
      EUS-share wave of the liver as a reliable diagnostic marker in patients with liver cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A non-blinded, prospective trial. Primary disease condition: liver cirrhosis Keywords: Liver&#xD;
      Cirrhosis; Fibrosis; Endoscopic Ultrasonography; Elasticity Imaging, Tissue.&#xD;
&#xD;
      Study Design: Observational study model: a non-blinded, non-randomized, prospective trial&#xD;
      Time perspective: prospective Enrollment type: actual Number of subjects: 16 participants&#xD;
      Number of groups/cohorts: 2 cohorts Target follow-up duration: 6 months&#xD;
&#xD;
      Based on the proportion of patients with the liver strain histogram (LSH) &gt;87.40 among&#xD;
      cirrhosis (87.5%) and control cases (31.0%) described by Robles-Medranda et al. (1), the&#xD;
      investigators calculated eight patients per study group with a 5% and 20% of alpha and beta&#xD;
      error respectively, with an 80% of power statistic.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">July 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of EUS-share of the liver</measure>
    <time_frame>2 months</time_frame>
    <description>Evaluation of the correlation between transient elastography, EUS-elastography of the liver, EUS-guided liver biopsy and EUS-guided share wave of the liver</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic accuracy of EUS-share wave of the liver</measure>
    <time_frame>2 months</time_frame>
    <description>Evaluate the diagnostic accuracy of EUS- share wave of the liver for predicting liver cirrhosis. Receiver operating characteristic curve development with evaluation of the sensitivity, specificity, PPV and NPV of EUS-guided share wave of the liver to predict liver cirrhosis.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Chronic liver disease with liver cirrhosis</arm_group_label>
    <description>Evaluation of the right and left hepatic lobe with EUS-guided share wave evaluation. All patients with chronic liver disease will have a transient elastography evaluation, EUS- elastography of the liver and an EUS-guided liver biopsy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control patients</arm_group_label>
    <description>Patients without history of chronic liver disease after clinical and transient elastography evaluation will be submitted for EUS-guided share wave evaluation of the liver. Patients were originally undergoing EUS evaluation for evaluation of suspected subepithelial lesions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>EUS- share wave of the liver</intervention_name>
    <description>Evaluation of the right and left hepatic lobe with EUS-guided share wave</description>
    <arm_group_label>Chronic liver disease with liver cirrhosis</arm_group_label>
    <arm_group_label>Control patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      EUS-guided liver biopsy&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Performed at Instituto Ecuatoriano de Enfermedades Digestivas (IECED), an academic tertiary&#xD;
        center in Guayaquil, Ecuador. Patients will be invited to participate during outpatient&#xD;
        clinic visits.&#xD;
&#xD;
        All consecutive participants need to be â‰¥18 years old and has a history of chronic liver&#xD;
        disease with histological proven liver cirrhosis. Control patients will be patients without&#xD;
        history of chronic liver disease and will be included following a transient elastography&#xD;
        test within normal limits.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provided informed written consent&#xD;
&#xD;
          -  Age greater than 18 years of age&#xD;
&#xD;
          -  Confirmed diagnosis of chronic liver disease based on transient elastography&#xD;
&#xD;
          -  Patients with EUS-guided liver biopsy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of uncontrolled coagulopathy&#xD;
&#xD;
          -  Contraindications to EUS-guided liver biopsy&#xD;
&#xD;
          -  Pregnancy or nursing&#xD;
&#xD;
          -  History of hepatocellular carcinoma&#xD;
&#xD;
          -  Patients with equivocal transient elastography results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ecuadorian Institute of Digestive Diseases</name>
      <address>
        <city>Guayaquil</city>
        <state>Guayas</state>
        <zip>090505</zip>
        <country>Ecuador</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos A Robles-Medranda, MD</last_name>
      <phone>+593989158865</phone>
      <email>carlosoakm@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Carlos A Robles-Medranda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hannah P Lukashok, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto A Oleas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel P Tejada, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ecuador</country>
  </location_countries>
  <results_reference>
    <citation>Robles-Medranda C, Oleas R, Puga-Tejada M, Valero M, Valle RD, Ospina J, Pitanga-Lukashok H. Results of liver and spleen endoscopic ultrasonographic elastography predict portal hypertension secondary to chronic liver disease. Endosc Int Open. 2020 Nov;8(11):E1623-E1632. doi: 10.1055/a-1233-1934. Epub 2020 Oct 22.</citation>
    <PMID>33140018</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver cirrhosis; fibrosis</keyword>
  <keyword>endoscopic ultrasonography</keyword>
  <keyword>elasticity imaging, tissue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

